Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29936263 | 1.00 | KMT2A (0.60) | KMT2AATMALDH1A1MAPTCRHBP | |
| SCHEMBL15247099 | 0.92 | KMT2A (0.55) | KMT2AATMALDH1A1MAPTCRHBP | |
| SCHEMBL28386352 | 0.89 | KMT2A (0.65) | KMT2AATMALDH1A1MAPTCRHBP | |
| SCHEMBL31591144 | 0.80 | TSHR (0.48) | KMT2AALDH1A1MAPTTSHRLMNA | |
| SCHEMBL25308546 | 0.79 | KMT2A (0.57) | KMT2AATMALDH1A1MAPTCYP1A2 | |
| SCHEMBL6726742 | 0.79 | KMT2A (0.50) | KMT2AATMMAPTKDM4E | |
| SCHEMBL28489841 | 0.79 | KMT2A (0.64) | KMT2AATMALDH1A1MAPTCRHBP | |
| SCHEMBL6726735 | 0.77 | KCNQ3 (0.41) | KMT2AATMALDH1A1MAPTKDM4E | |
| SCHEMBL416586 | 0.77 | KCNQ3 (0.41) | KMT2AATMALDH1A1MAPTKDM4E | |
| SCHEMBL29525674 | 0.77 | KCNQ3 (0.41) | KMT2AATMALDH1A1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022117714-A1 | IMAGING METHODS AND RADIOTRACERS FOR USE THEREIN | VESTLANDETS INNOVASJONS SELSKAP AS (VIS) (NO) | 2022-06-09 | — | — | WO | disclosed |
| EP-3353152-B1 | METHOD | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2021-09-15 | — | — | EP | disclosed |
| US-10869942-B2 | Method | NORSK MEDISINSK SYKLOTRONSENTER AS (NO) | 2020-12-22 | — | — | US | disclosed |
| US-8530620-B2 | Radiolabelling reagents and methods | GE HEALTHCARE LIMITED (GB) | 2013-09-10 | — | — | US | disclosed |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869942-B2 | Method | MPI, DUT, NT5E | KMT2A 3393/4885ATM 4369/4885ALDH1A1 1340/4885 |
| US-20120022227-A1 | RADIOLABELLING REAGENTS AND METHODS | ANPEP, DNPEP, QRFPR | KMT2A 3853/4885ATM 4038/4885ALDH1A1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.